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ABSTRACT
Objective The objective of the study is to compare body 
mass index (BMI), systolic/diastolic blood pressure (SBP/
DBP) and serum total cholesterol levels between dementia 
cases and controls at multiple time intervals prior to 
dementia onset, and to test time interval as a modifying 
factor for these associations.
Design Case–control study.
Setting Six European electronic health records databases.
Participants 291 780 cases at the date of first- recorded 
dementia diagnosis, compared with 29 170 549 controls 
randomly selected from the same databases, age matched 
and sex matched at this index date.
Exposure The following measures were extracted 
whenever recorded within each dataset: BMI (kg/m2), SBP 
and DBP (mm Hg) and serum total cholesterol (mmol/L). 
Levels for each of these variables were defined within six 
2- year time intervals over the 12 years prior to the index 
date.
Main outcomes Case–control differences in exposures 
of interest were modelled for each time period 
and adjusted for demographic and clinical factors 
(ischaemic/unspecified stroke, type 2 diabetes mellitus, 
acute myocardial infarction, hypertension diagnosis, 
antihypertensive medication, cholesterol- lowering 
medication). Coefficients and interactions with time period 
were meta- analysed across the six databases.
Results Mean BMI (coefficient −1.16 kg/m2; 95% CI 
–1.38 to 0.93) and SBP (−2.83 mm Hg; 95% CI –4.49 to 
–1.16) were lower in cases at diagnosis, and case–control 
differences were greater in more recent time periods, 
as indicated by significant case- x- time interaction and 
case- x- time- squared interaction terms. Time variations 
in coefficients for cholesterol levels were less consistent 
between databases and those for DBP were largely not 
significant.
Conclusion Routine clinical data show emerging 
divergence in levels of BMI and SBP prior to the 
diagnosis of dementia but less evidence for DBP or total 
cholesterol levels. These divergences should receive 
at least some consideration in routine dementia risk 
screening, although underlying mechanisms still require 
further investigation.
INTRODUCTION
Vascular risk factors are widely recognised 
as important in the aetiology of dementia; 
however, observed associations depend on 
the timing of measurement. For example, 
higher blood pressure (BP) (particularly 
Strengths and limitations of this study
 ► We have investigated associations of blood pres-
sure, body mass index and cholesterol levels with 
dementia and the time dependency of such obser-
vations, using what we believe to be currently the 
largest confederation of health records data.
 ► There are advantages in the generalisability of rou-
tine data and in patient populations who are less 
subject to participation selection than research 
cohorts.
 ► The use of multiple data resources allowed the 
consistency of associations to be evaluated, as it is 
particularly important for clinical ‘big data’ where 
large sample sizes result in even very minor asso-
ciations being identified as statistically significant, 
and where traditional heterogeneity statistics from 
meta- analyses are similarly uninformative.
 ► The limitations of the study are those that typify rou-
tine administrative rather than research data, in that 
measurements were limited to those recorded in 
routine practice which could be harmonised across 
the six databases, and the stage of dementia at di-
agnosis was not known.
 ► While the large samples will have reduced the im-
pact of missing data on statistical power, potential 
bias arising from non- random missingness cannot 
be excluded, although we feel it is unlikely to ac-
count for the findings of interest.
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systolic BP; SBP) in mid- life is a predictor of dementia 
10–20 years later,1–3 but people with dementia tend to 
have lower BP at the time of the clinical onset than age- 
matched controls,1 accounted for by an exaggerated 
decline in SBP prior to the onset of dementia.4–6 Similar 
associations have been observed for body mass index 
(BMI), with mid- life obesity associated with increased risk 
of dementia,7 8 but dementia clinical onset associated with 
lower contemporaneous BMI9 and preceded by acceler-
ated weight loss.10 Finally, higher mid- life cholesterol has 
been found to predict dementia in some studies,11 and a 
decline in cholesterol levels prior to dementia onset has 
been observed in others.12 13
These findings have arisen almost exclusively from 
specifically recruited research cohorts followed over long 
periods—advantageous in many respects but potentially 
subject to selection, and therefore limited generalisability. 
The parameters of interest (BP, BMI, cholesterol levels) 
are routinely measured in clinical practice, but there has 
been no investigation of their associations with dementia 
and the time- dependency of such observations. We sought 
to pursue this in what we believe to be currently the largest 
confederation of health records data—that enabled by the 
European Medical Information Framework Innovative 
Medicines Initiative (EMIF- IMI) within which an Alzhei-
mer’s Disease (EMIF- AD) consortium was developed. 
The objective of the study reported here was to compare 
levels of the exposures of interest between dementia cases 
and controls at multiple time intervals prior to dementia 
onset, and to test time interval as a modifying factor for 
these associations. The specific hypothesis was that BMI, 
SBP and diastolic BP (DBP) and serum total cholesterol 
would be lower in people with newly diagnosed dementia 
than in controls, and that these differences would have 
widened closer to the diagnosis date. In this study, we 
used data from several European national or regional 
databases—both primary care general practitioner (GP) 
records and hospital based databases—containing a total 
number of over 22.5 million patients who used mainly 
public/national health services.
METHODS
Data resources
EMIF- IMI worked with several electronic health record 
(EHR) resources to render data available for analysis 
with appropriately robust data security and governance. 
EMIF datasets participating in a recent investigation of 
incidence and prevalence of diagnosed dementia were 
estimated to contain information on 182 776 people with 
a dementia diagnosis, with around 1 000 000 person- years 
of data prior to the diagnosis and 400 000 person- years 
after the diagnosis.14 These resources included three 
primary care databases from the Netherlands, Italy and 
UK (Integrated Primary Care Information (IPCI), Health 
Search Database (HSD) and The Health Improvement 
Network (THIN) respectively) and two hospital catch-
ment area databases in Jutland and Barcelona (Aarhus 
University Hospital Database (AUH) and Information 
System of Parc de Salut Mar (IMIM- UPF), respectively). 
In this study, the ‘Information System for Research in 
Primary Care (SIDIAP), containing Catalan primary care 
records) was added as a new database. The final assem-
bled data resource included a total 291 780 patients with 
a dementia diagnosis across the six databases.
The THIN database contains data from participating 
UK primary care services with records from 1990 on 
around 9 million patients in total and 4 million receiving 
active care at a given time. Demographic profiles have 
been found to be similar to national estimates although 
THIN contains fewer people aged under 25 years; condi-
tion prevalence has also been found to be comparable.15 
The IPCI database is drawn from primary care records 
in Netherlands since 1990 on around 2.6 million patients 
in total, and 1.4 million receiving active care; its data are 
drawn from what has been found to be a representa-
tive sample (n=750) of GPs in the Netherlands.16 AUH 
is a regional record linkage system in Aarhus, Denmark 
containing both inpatient and outpatient records since 
1989 with 1.8 million active patients, drawing data 
from different public bodies and including all ages.17 
IMIM- UPF contains hospital data from the Barcelona 
region with 1.6 million active patients and including all 
hospital admissions. HSD contains primary care records 
in Italy with nearly 2.3 million patient records from more 
than 800 participating primary care services throughout 
Italy: a longitudinal observational database that has been 
found to be representative of the general Italian popula-
tion, established in 1998 by the Italian College of General 
Practitioners.18 SIDIAP contains primary care records 
from Catalonia in Spain with nearly 6 million patient 
records from family paediatricians and GP medical 
records and data from all ages.17
The EMIF project, funded through the IMI programme 
(Innovative Medicines Initiative Joint Undertaking under 
grant agreement no. 115372), had designed and imple-
mented a federated platform to connect health data from 
a variety of sources across Europe, to facilitate large scale 
clinical and life sciences research. It enabled approved 
users to analyse securely multiple, diverse, data via a 
single portal, thereby mediating research opportunities 
across a large quantity of research data. EMIF developed 
a code of practice (ECoP) to ensure the privacy protec-
tion of data subjects, protect the interests of data sharing 
parties, comply with legislation and various organisa-
tional policies on data protection, uphold best practices 
in the protection of personal privacy and information 
governance, and eventually promote these best practices 
more widely. EMIF convened an Ethics Advisory Board, 
to provide feedback on its approach, platform, and the 
EcoP19 and all use of the data resources described was 
carried out with full approval of the data owners and thus 
complied with pre- existing governance specifications for 
secondary analysis.
This study created an age- matched and sex- matched 
case–control study, comparing people with and without 
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dementia on prior exposures of interest over the 
preceding 12 years, adjusting for relevant and available 
covariates, and investigating time interval as a modifying 
factor.
Population
Cases were defined on the basis of a diagnosis of dementia 
and included all assigned dementia diagnoses of any type 
(inclusion criterion) and the index date was set as that 
on which the first dementia diagnosis was recorded. The 
definition of dementia was extensively developed and 
harmonised across the EMIF- AD consortium, taking into 
account the different coding systems used, as previously 
described in detail including supplementary data on code 
lists applied.14 For each case, at the index date of first 
dementia diagnosis, 100 controls were drawn randomly 
from the same EHR, matched to the case on gender and 
age (±2 years) at that index date, having excluded any 
dementia at or prior to that date. When there were not 
enough controls, one control was allowed to be used for 
several cases. Both cases and controls were restricted to 
people aged 50 years or over at the index date.
Exposures
The following measures were extracted whenever recorded 
within each dataset: BMI (kg/m2), SBP (mm Hg), DBP 
(mm Hg) and serum total cholesterol (mmol/L). BMI 
was extracted where recorded, or was calculated from 
recorded body weight and height data. Levels for each of 
these variables were defined within six 2- year time inter-
vals over the 12 years prior to the index date, taking mean 
values if multiple measures were present for an individual 
within each interval. Percentages of missing data points 
were compared between cases and controls, and by age, 
sex and comorbidities.
Covariates
Data on age at index date and gender were extracted. 
In addition, the following binary variables were gener-
ated based on any recorded diagnosis/treatment prior 
to the index date: ischaemic/unspecified stroke, type 2 
diabetes mellitus (diagnosis or antidiabetic medication), 
acute myocardial infarction, hypertension diagnosis, 
use of any antihypertensive medication and use of any 
cholesterol- lowering medication. Hypertension diagnosis 
was considered as a relevant covariate as patients with 
sustained hypertension in midlife have an increased risk 
for dementia regardless of their BP during late life20 and 
because the interest was on changes in the BP relationship 
over time, which was not considered to be coterminous 
with a hypertension diagnosis. Medication information 
was extracted from databases in which it was available 
from recorded prescriptions or dispensations; disorders 
were defined according to pre- existing harmonised data 
extraction criteria used across the EMIF- IMI consortia.21
Statistical analysis
The total pool of cases and controls were first described 
in terms of demographic and clinical covariates, followed 
by a descriptive analysis of data availability on the expo-
sures of interest.
General linear model (GLM) analyses were used for 
each database and for each of the four parameters of 
interest, to model case–control differences in mean expo-
sure levels separately for each comparison time period 
and to adjust for covariates. Importantly, each time period 
comparison was treated as a separate analysis for case–
control sets with data present in that time period and 
covariate adjustments for each comparison, rather than 
in terms of repeated observations within individuals. The 
exposures here were modelled as dependent variables, 
with main independent variables being case–control 
status, time category, interaction between case–control 
status and time category, age at index date, sex, the four 
vascular disorders described above and stratum variable. 
Based on plots of unadjusted mean differences by time 
period, linear time terms were used for DBP as a depen-
dent variable while quadratic time terms were added to 
models of BMI, SBP and total cholesterol.
Having finalised models for each of the four parameters 
(BMI, SBP, DBP, total cholesterol) in each EHR dataset, 
the GLM coefficients for each dataset were pooled in a 
meta- analysis for each parameter. Random effects were 
assumed when coefficients were pooled. In secondary 
analyses, adjusted meta- analysed coefficients for SBP, 
DBP and total cholesterol were stratified as appropriate 
according to previously received antihypertensive or lipid 
lowering medication in cases and controls. The signifi-
cance level for all tests was defined as a p≤0.05. Analyses 
were carried out using IBM SPSS Statistics V.20.0.
Patient and public involvement
The was no specific patient or public involvement in the 
design or interpretation of this particular study.
RESULTS
Overall, there were 291 780 dementia cases (ranging from 
3433 cases in IMIM- UPF to 139 083 cases in THIN) and 
29 170 549 controls made available for analysis from all six 
EHR databases. As described in table 1, age and sex were 
effectively matched in cases and controls. Higher propor-
tions of cases had a history of diabetes, acute myocar-
dial infarction and stroke. Slightly higher proportions 
of cases had been prescribed antihypertensive, as well as 
lipid lowering, medication than controls; however, preva-
lence of recorded hypertension did not differ consistently 
between cases than controls across the databases. Descrip-
tive data on mean vascular risk factor levels by case/
control status, time period and database are provided in 
online supplemental table 1, missing data percentages by 
year and case status in online supplemental table 2, and 
missing data by covariates in online supplemental table 
3. Missing data were more prominent for less recent time 
periods; for time periods over 2 years before the index 
date, missing data were more common in cases than 
controls, but more common in controls than cases for the 
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0–2 years time period; missing data were least common for 
SBP/DBP and most common for BMI. Mean numbers of 
missing data points were not found to vary consistently by 
age or sex, although missing data were consistently below 
mean levels in those with hypertension and above mean 
levels in those with stroke. Online supplemental file 1 
summarises proportions of patients with missing data for 
each vascular risk factor in each database. In summary, 
AUH had limited BMI data, with no values prior to 6 years 
before the index date and no data for SBP and DBP. For 
HSD, 94% of BMI data were missing in the 10–12 years 
window before the index date, improving to 78% by the 
0–2 years window and similar trends were observed for 
BMI data in the IPCI database, with 93% missing at 10–12 
years and 67% missing data at 0–2 years before the index 
date. In the SIDIAP database there were no BMI, BP or 
total cholesterol data at 10–12 years before the index 
date. Generally, compared with other databases, there 
were fewer missing data in the THIN database for all risk 
factors. IMM- UPF did not have BP data, and had no BMI 
data at 10–12 years before the index date.
Figure 1 displays case–control differences in vascular 
risk factor exposures of interest by time and database. For 
BMI, the largest decline in meta- analysed case–control 
differences was observed between 2–4 years and 0–2 years 
before the index diagnosis of dementia. For SBP, the 
meta- analysed case–control difference increased from 
8–10 years to 4–6 years and then declined steeply from 
2–4 years to 0–2 years. For DBP, the largest meta- analysed 
case–control differences were observed in the 2–4 years 
and 0–2 years periods before the diagnosis of dementia. 
For total serum cholesterol levels, the meta- analysed case–
control difference increased from 10–12 years to 6–8 years 
before the diagnosis of dementia and then declined up 
till the diagnosis of dementia with a slightly large decline 
just before diagnosis of dementia. For all exposures apart 
from DBP, cases had lower values compared with controls 
(negative case coefficients), all four exposures decreased 
in later time periods (negative time coefficients) and this 
was more marked for cases compared with controls (nega-
tive case- x- time interaction terms) (table 2). Quadratic 
terms were also significant and negative in value for BMI 
and SBP, reflecting the curvilinear relationships displayed 
in figure 1, while those for total cholesterol comprised 
a positive time- squared term and a negative case- x- time- 
squared interaction, again reflecting the curvilinear visu-
alised relationship. Following adjustment for covariates, 
case- x- time and case- x- time- squared interaction terms 
were reduced modestly for BMI and SBP but retained 
statistical significance. No significant case or case- x- time 
terms were observed for DBP. For total cholesterol a 
negative- value case- x- time interaction term persisted, 
but there was no longer a significant case- x- time- squared 
interaction.
Following additional stratification of these adjusted 
models by medication use (table 3), SBP coefficients were 
not markedly different (overlapping confidence inter-
vals), although those for case status and the case- x- time T
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interaction were stronger in the subgroups who were 
not receiving antihypertensive medication; the (negative 
value) case coefficient for DBP was also stronger in that 
subgroup. Likewise, case and case- x- time coefficients for 
total cholesterol levels were stronger in those not receiving 
lipid lowering medication, although CIs overlapped.
DISCUSSION
In this large study spanning 12 years, we compared people 
with/without a dementia diagnosis and investigated previ-
ously recorded levels of BMI, SBP, DBP and total serum 
cholesterol. In summary, BMI, SBP and total cholesterol 
levels were lower overall in cases with dementia than 
Figure 1 Mean differences between cases and controls in vascular risk factor exposures of interest by database and time prior 
to index date. AUH, Aarhus University Hospital Database; BMI, body mass index; DBP, diastolic blood pressure; HSD, Health 
Search Database; IPCI, Integrated Primary Care Information; IMIM- UPF, Information System of Parc de Salut Mar; SBP, systolic 
blood pressure; SIDIAP, Information System for Research in Primary Care; THIN, The Health Improvement Network.
Table 2 Meta- analysed unadjusted GLM coefficients (with 95% CIs) across component databases for the relationships 
between case/control status, time period and the four outcomes of interest
BMI SBP* DBP*† Cholesterol
Unadjusted
  Intercept 31.6 (31.6 to 31.6) 114.6 (114.5 to 114.6) 84.4 (84.4 to 84.4) 5.4 (5.3 to 5.5)
  Case −1.32 (−1.41 to −1.21) −3.25 (−3.34 to −3.16) 0.04 (−0.03 to 0.11) −0.12 (−0.20 to −0.04)
  Time −0.11 (−0.17 to −0.06) −1.06 (−1.17 to −0.98) −0.54 (−0.61 to −0.45) −0.03 (−0.05 to −0.01)
  Case- x- time −0.27 (−0.32 to −0.19) −0.63 (−0.72 to −0.57) −0.03 (−0.06 to −0.01) −0.03 (−0.04 to −0.02)
  Time squared −0.06 (−0.10 to −0.02) −0.13 (−0.19 to −0.07) 0.01 (0.00 to 0.02)
  Case- x- time squared −0.02 (−0.03 to −0.01) −0.14 (−0.21 to −0.10) −0.01 (−0.01 to −0.00)
Adjusted‡
  Intercept 31.5 (30.9 to 32.2) 117.6 (108.8 to 126.5) 87.0 (81.7 to 92.3) 5.18 (4.89 to 5.50)
  Case −1.16 (−1.38 to −0.93) −2.83 (−4.49 to −1.16) −0.19 (−0.46 to 0.08) −0.10 (−0.17 to -0.04)
  Time −0.13 (−0.16 to −0.10) −0.83 (−1.16 to −0.50) −0.50 (−0.57 to −0.42) −0.05 (−0.07 to −0.02)
  Case- x- time −0.18 (−0.28 to −0.08) −0.53 (−0.80 to −0.26) 0.00 (−0.06 to 0.06) −0.05 (−0.09 to −0.01)
  Time squared −0.01 (−0.08 to 0.06) −0.01 (−0.02 to 0.02) 0.00 (−0.02 to 0.02)
  Case- x- time squared −0.01 (−0.02 to −0.00) −0.04 (−0.05 to −0.02) −0.01 (−0.01 to 0.01)
*SBP and DBP not available in AUH or IMIM- UPF.
†Based on linear equation.
‡GLM coefficients adjusted for age, sex, diabetes, hypertension, acute myocardial infarction and stroke.
AUH, Aarhus University Hospital; BMI, body mass index; GLM, general linear model; IMIM- UPF, Information System of Parc de Salut 
Mar; SBP/DBP, systolic/diastolic blood pressure.
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controls and the difference was most marked closest to 
the point of diagnosis. This time dependency of the asso-
ciations was not accounted for by age, sex or recorded 
vascular disorders, and case–control differences in SBP 
and total cholesterol did not appear to be modified by 
antihypertensive or lipid- lowering treatment respec-
tively. There was little evidence for associations with DBP 
after adjustment, and between- database heterogeneity 
appeared high for associations with total cholesterol, 
unlike the relative consistency observed with BMI and 
SBP. As described, while dementia is generally found to 
be associated with higher levels of vascular risk factors 
measured 10–20 years before its clinical onset in prospec-
tive epidemiological studies, associations are often found 
to be reversed when investigated closer to time of this 
clinical onset.22 The extent to which these associations 
can be observed in more healthcare data remains to be 
established, despite opportunities for assessing this over 
large, ‘real- world’ populations.
Considering BMI, prospective studies with decades 
follow- up23 have suggested that midlife obesity is a risk 
factor for dementia,24 but this association is attenuated 
or reversed in older age,25 and exaggerated weight loss 
precedes the clinical onset of dementia,26 described for 
periods of 2–4 years,27 5 years28 or up to 10 years29 before 
dementia onset. Our findings of lower SBP in cases at 
the time of diagnosis, and a preceding widening differ-
ence over time, are also consistent with epidemiological 
research, as is the lack of association with DBP: high 
mid- life SBP is a risk factor for dementia incidence 10–20 
years later,2 3 5 while SBP at dementia clinical onset tends 
to be lower than controls,5 30 and exaggerated decline in 
SBP prior to dementia has been described in Swedish4 31 
and Japanese American6 cohorts, as well as during the 
course of dementia.32 Although case and case- x- time coef-
ficients were statistically significant for total cholesterol 
levels, similar to those for BMI and SBP, visual inspection 
(figure 1) indicated considerably more inconsistency 
between databases and we feel that conclusions are less 
strong in this respect. The relationship between choles-
terol level and dementia has been less clear in epidemio-
logical research,33 although tends to support associations 
with high total cholesterol mid- life but not in late- life. 
Declining cholesterol levels precede dementia,12 13 
although without the later acceleration described for BMI 
and SBP, and not observed in all studies.34
Assuming that the widening gaps in exposure levels 
between cases and controls in our data reflect dementia- 
associated decline in these factors, underlying causal path-
ways may vary. Weight loss might be secondary to early 
neurodegeneration, reflecting a combination of prede-
mentia apathy, loss of initiative and reduced olfactory 
function.29 Cholesterol decline in one study was observed 
to occur over 10 years before dementia clinical onset, 
followed by a parallel trajectory,13 so could conceivably be 
a marker for another risk factor, such as an episode of 
infection or inflammation resulting in both the decline 
in cholesterol and increased later risk of dementia. While 
declining BP might be secondary to early neurodegen-
eration, it might also represent a risk factor in itself, 
through reduced cerebral perfusion and watershed 
ischaemia/infarction, and/or might be a consequence 
of previous untreated hypertension. The role of anti-
hypertensive treatment in accounting for or modifying 
predementia blood pressure decline has been controver-
sial. In one cohort, the exaggerated dementia- associated 
decline in SBP was found to be restricted to people who 
had not received antihypertensive agents,6 and associ-
ations between dementia and lower contemporaneous 
BP were found to be weak or absent in populations from 
low- income and middle- income countries where hyper-
tension is uncommon.35 However, other cohorts have 
found stronger contemporaneous associations between 
dementia and lower BP in people receiving antihyper-
tensives36 or no modification of later SBP decline.31 In 
our databases, the coefficients of interest (ie, for case 
and case- x- time) were stronger in the subgroup who had 
not received antihypertensive treatment, but differences 
were not substantial and confidence intervals overlapped. 
The same was true for associations with cholesterol levels, 
which were also marginally stronger in the subgroup who 
had not received lipid lowering treatment, although no 
attempt was made to factor in treatment differences in 
lipid- lowering effectiveness.
In previous research, there has been some suggestion 
of an age- dependent effect of BP on AD, although the 
evidence is relatively weak: there was a suggestion that 
Table 3 Meta- analysed adjusted GLM coefficients stratified 
by antihypertensive treatment and lipid lowering medication
SBP
With antihypertensive 
treatment
No antihypertensive 
treatment
Intercept 121.6 (115.5 to 127.8) 109.4 (101.4 to 117.5)
Case −2.44 (−3.56 to −1.33) −4.02 (−8.67 to 0.63)
Time −1.01 (−1.40 to −0.62) −0.14 (−0.55 to 0.28)
Case- x- time −0.49 (−0.60 to −0.32) −0.72 (−1.54 to 0.10)
Time squared −0.03 (−0.04 to −0.01) −0.04 (−0.05 to −0.02)
Case- x- time squared −0.04 (−0.05 to −0.03) −0.04 (−0.08 to 0.01)
DBP With antihypertensive 
treatment
No antihypertensive 
treatment
Intercept 89.3 (85.8 to 92.9) 82.3 (76.1 to 88.5)
Case −0.05 (−0.43 to 0.33) −1.07 (−1.57 to −0.56)
Time −0.55 (−0.64 to −0.50) −0.15 (−0.22 to −0.08)
Case- x- time 0.02 (−0.02 to 0.07) −0.11 (−0.29 to 0.07)
Cholesterol With lipid- lowering 
drugs
No lipid- lowering 
drugs
Intercept 5.23 (5.20 to 5.25) 5.44 (5.18 to 5.71)
Case 0.02 (−0.01 to 0.05) −0.08 (−0.12 to −0.03)
Time −0.07 (−0.10 to −0.04) −0.02 (−0.06 to 0.02)
Case- x- time −0.01 (−0.01 to 0.01) −0.03 (−0.04 to −0.02)
Time squared −0.03 (−0.04 to −0.01) −0.04 (−0.05 to −0.02)
Case- x- time squared −0.01 (−0.02 to 0.00) −0.01 (−0.01 to −0.00)
GLM, general linear model; SBP/DBP, systolic/diastolic blood pressure.
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mid- life diastolic, but not midlife systolic, hypertension in 
midlife may increase risk of incident AD and a sugges-
tion that elevated late- life BP may actually be beneficial.37 
However, the same systematic review37 and meta- analysis 
of prospective epidemiological research, did not provide 
clear evidence for a relationship between BP and inci-
dence of AD. On the other hand,38 higher SBP was found 
among patients with vascular dementia (OR per 10 mm 
Hg: 1.33). Several well- established longitudinal studies 
have reported on the relationships between the trajectory 
of change over time in levels of BP, cholesterol and BMI 
and incident all- cause dementia, with some additionally 
reporting on AD, vascular dementia and MCI.39 Authors 
found that the results for AD, vascular dementia and MCI 
were similar but with fewer data points, with those who 
went on to develop all- cause dementia showing a greater 
increase, followed by a sharper decrease in BP and/or 
BMI before a positive diagnosis.
In a collaborative study of over 1.3 million adults from 
Europe, the USA and Asia, higher BMI was associated 
with increased dementia risk when weight was measured 
>20 years before dementia diagnosis,40 but this associa-
tion was reversed when BMI was assessed <10 years before 
dementia diagnosis and this finding is consistent with 
our study as well as a systematic review.41 Furthermore, 
comparisons of risk factors for dementia, AD and VaD, in 
developed and developing world regions were carried out 
in a review by Kalaria in 2010 which concluded that there 
was a high risk effect of factors such as vascular diseases 
and smoking for incidence of dementia in developed 
regions (North America, Europe, Japan) as well as in Asia 
(China, Guam, India, South Korea, Taiwan). Dementia 
was significantly associated with reported stroke and 
diabetes in logistic regression models adjusted for socio-
demographic status and other vascular risk factors (OR 
4.40 (95% CI 2.70 to 7.19) and OR 1.56 (95% CI 1.20 to 
2.03), respectively) in a national survey of older people 
in Trinidad.42
Information on education level was not available in 
these routine healthcare data resources. On the one 
hand, low educational achievement has been shown to 
be a robust risk factor for dementia43; on the other hand, 
intellectually stimulating, socially engaging, or physical 
activities might lower the risk of dementia.44 The situa-
tion is not different in low/middle- income countries, 
where surveys have consistently identified low education 
as a risk factor for dementia.45 However, in some commu-
nities, low literacy is often linked to poverty or lower 
socioeconomic status, which is also associated with poorer 
health, lower access to healthcare and increased risk 
of dementia.45 While it may well be the case that lower 
education confers both a higher risk of dementia and a 
higher risk of adverse vascular risk factors, it is less clear 
whether there should be any association between educa-
tion and the changes over time in relationships between 
vascular risk factors and dementia, described in this study.
Our study has several strengths. We believe that the data 
resource used for this analysis is the largest deployed to 
date in dementia research by a considerable margin, illus-
trating the potential value of routine healthcare data and 
increasing accessibility of EHRs for research use within 
robust governance frameworks such as that developed by 
the EMIF- IMI consortium. In addition, there are advan-
tages in the generalisability of routine data and in patient 
populations who are less subject to participation selection 
than research cohorts. Finally, the use of multiple data 
resources allowed the consistency of associations to be 
evaluated. This is particularly important for clinical ‘big 
data’ where large sample sizes result in even very minor 
associations being identified as statistically significant, 
and where traditional heterogeneity statistics from meta- 
analyses are similarly uninformative; this is exemplified in 
the visualisation of associations with DBP and total choles-
terol (figure 1) where reported analyses from single data-
bases might have given rise to conclusions which are not 
consistent across others.
The limitations of the study are those that typify 
routine administrative rather than research data. 
Measurements were limited to those recorded in 
routine practice which could be harmonised across 
the six databases, bearing in mind the different clin-
ical coding systems used. For this reason, and as previ-
ously described14 dementia was defined as a composite 
outcome with no attempt to identify subtypes which are 
less consistently ascertained in routine clinical prac-
tice. Covariates were limited to demographic factors, 
common disorders and specific medication groups 
of interest, and did not include measures of socio-
economic status or lifestyle factors such as smoking 
status, diet, or physical activity. Missing data are also an 
important consideration. While the large samples will 
have reduced the impact of missing data on statistical 
power, potential bias arising from non- random missing-
ness cannot be excluded, although we feel it is unlikely 
to account for the findings of interest. As displayed 
in online supplemental table 2, the strongest influ-
ence on data loss was time, with more missing data in 
earlier time periods, as would be expected in clinical 
samples (where routine exposure checks will be more 
common in older age groups). Therefore, case–control 
differences at earliest time points should be viewed 
with caution. Furthermore, two databases, AUH and 
IMIM- UPF, did not contribute BP data and IMIM- UPF 
and HSD had high proportion of missing data for BMI 
throughout the study period. However, it is hard to 
envisage how differential missing data could account 
for lower exposure levels in future cases, or for the 
widening of case–control differences over time (since 
this was not observed for all exposures of interest). 
Furthermore, influences of age, sex and comorbidity 
on missingness were relatively minor, apart from under-
standable higher recording in monitored conditions 
such as hypertension. Finally, although missing data 
were more common in cases than controls for most 
time periods, these differences were not substantial. 
Consideration was given to missing data when analyses 
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were planned; however, the limited level of covariate 
ascertainment and potential non- random missingness 
were felt to preclude imputation approaches.
An important consideration with dementia diagnoses 
in routine healthcare data from non- specialist services 
is that there is minimal or no information on the stage/
severity of dementia at diagnosis, because of the absence 
of structured data on cognitive function. While some 
people will have received a dementia diagnosis early in 
the course of the condition, others may receive this after 
several years of significant symptoms. For example, the 
length of time between dementia symptoms being noticed 
and diagnosis of dementia has been estimated to vary in 
Europe from 1.61 years in Italy to 2.49 years in Scotland 
and 2.57 years in Netherlands.46 Therefore, comparisons 
are limited with epidemiological cohorts using dementia 
screening protocols. At least some of the widening differ-
ence in exposure levels between cases and controls may, 
therefore, have occurred during times when dementia 
was evident but undiagnosed. Finally, our analyses did not 
analyse exposure trajectories within individuals, which 
is the standard approach in epidemiological cohorts. 
Instead we investigated case–control differences in previ-
ously recorded exposures at different times, hypothe-
sising that the dementia- associated trajectories previously 
reported for these factors would manifest in variation of 
case–control differences across time periods, and hence 
case- x- time interaction in the statistical models.
CONCLUSION
In summary, considering our observations at group level, 
there are clear potential implications for clinical services 
which require further evaluation. For example, there 
might be good reason for individual trajectories to be 
more effectively monitored (eg, BMI or SBP change), 
possibly enhanced by EHR systems that could highlight 
changes over time and the need for more frequent 
assessment or supplementary cognitive assessment for 
earlier risk- identification. In addition, regardless of 
causation, the potential consequences of low BMI/SBP 
as comorbidities in dementia have yet to be fully clari-
fied (eg, as risk factors for falls or functional decline) 
which again might have implications for future routine 
monitoring. In examining the patterns and trajectories 
of the established risk factors for cognitive decline and 
dementia, this study adopted a relatively broad approach 
to an emerging area of enquiry. Our study focused on 
three risk factors of interest that were envisaged to be 
most available (BP, cholesterol and BMI); however, 
future work could feasibly include greater numbers of 
risk factors and the interaction between different indi-
vidual changes in status (eg, the combination of changes 
in BP and BMI), which could eventually lead to more 
personalised risk assessments and targeted interventions 
early in the asymptomatic, prodromal phase of cognitive 
decline and dementia.
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